1
|
Furukawa K, Yamamura T, Nakamura M, Kawashima H, Fujishiro M. Gastrointestinal: Idiopathic omental hemorrhage. J Gastroenterol Hepatol 2022; 37:282. [PMID: 34390039 DOI: 10.1111/jgh.15639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/29/2021] [Accepted: 07/22/2021] [Indexed: 12/09/2022]
Affiliation(s)
- K Furukawa
- Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - T Yamamura
- Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - M Nakamura
- Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - H Kawashima
- Department of Endoscopy, Nagoya University Hospital, Nagoya, Japan
| | - M Fujishiro
- Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
2
|
Suzuki H, Ishikawa T, Ohno E, Kawashima H, Fujishiro M. Gastrointestinal: Pancreatic metastasis from extramammary Paget's disease diagnosed by endoscopic ultrasound-guided fine-needle biopsy. J Gastroenterol Hepatol 2021; 36:3000. [PMID: 33719120 DOI: 10.1111/jgh.15444] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/12/2021] [Accepted: 02/14/2021] [Indexed: 12/09/2022]
Affiliation(s)
- H Suzuki
- Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - T Ishikawa
- Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - E Ohno
- Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - H Kawashima
- Department of Endoscopy, Nagoya University Hospital, Nagoya, Japan
| | - M Fujishiro
- Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
3
|
Gamal Setih A, Hara H, Tomaniak M, Lunardi M, Gao C, Ono M, Kawashima H, Juni P, Vranckx P, Windecker S, Hamm C, Gabriel Steg P, Onuma Y, Serruys P. Efficacy and safety of early aspirin withdrawal and continuation of ticagrelor monotherapy post PCI for STEMI. A post hoc analysis of the randomized global leaders trial. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2998] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Clinical presentation with STEMI is considered as a highly prothrombotic condition often associated with recurrent ischemic events. The role of aspirin as part of antiplatelet regimens in STEMI patients needs to be clarified especially in the context of new potent P2Y12 inhibitors
Aim
To assess the benefit and risk of 23-month ticagrelor monotherapy after one month of DAPT against the conventional 12-month DAPT with aspirin and ticagrelor followed by aspirin monotherapy among STEMI patients in the GLOBAL LEADERS trial.
Methods
We did a post hoc analysis of STEMI patients in the GLOBAL LEADERS trial (2092 patients). We compared the experimental ticagrelor monotherapy group (1062 patients) with the standard 12-month DAPT group (1030 patients) in rates of GLOBAL LEADERS predefined primary (composite of all-cause mortality or non-fatal, new Q-wave myocardial infarction (MI) and secondary end points (BARC 3 or 5 bleeding). NACE (Net Adverse Clinical Events) and POCE (Patient- Oriented Composite End points). We also compared GLOBAL LEADERS predefined end points in STEMI, UA, NSTEMI and CCS in both treatment arms.
Results
At two years, there were no significant differences in rates of GLOBAL LEADERS primary end points in patients who had or did not have STEMI. BARC bleeding in either treatment group didn't vary significantly among STEMI, NSTEMI and UA. Nevertheless, the experimental strategy had led to significant increase in BARC bleeding in CCS compared with STEMI at 1 and 2 years. There were similar rates of NACE and POCE in both the experimental and reference treatment groups at 1 and 2 years post PCI.
Conclusions and relevance
The incidence of GLOBAL LEADRER defined end points has not been impacted by STEMI presentation. Our findings suggest that an earlier cessation of DAPT at 1 month post primary PCI, with continuation of a potent P2Y12 antagonist monotherapy, could be safe and avoids additional bleeding risk in the STEMI setting. Given the post-hoc nature of the analysis, our findings should not necessitate changes in recommendations for practice by professional associations and regulatory agencies. However, all reported findings should rather be considered only as hypothesis-generating and need be replicated in dedicated large-scale randomized trials to further assess the role of Aspirin free antithrombotic strategies post PCI in STEMI.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- A Gamal Setih
- National University of Ireland Galway, Galway, Ireland
| | - H Hara
- National University of Ireland Galway, Galway, Ireland
| | - M Tomaniak
- Medical University of Warsaw, Warsaw, Poland
| | - M Lunardi
- National University of Ireland Galway, Galway, Ireland
| | - C Gao
- National University of Ireland Galway, Galway, Ireland
| | - M Ono
- National University of Ireland Galway, Galway, Ireland
| | - H Kawashima
- National University of Ireland Galway, Galway, Ireland
| | - P Juni
- St. Michael's Hospital, Toronto, Canada
| | - P Vranckx
- Heart Centre Hasselt, Hasselt, Belgium
| | - S Windecker
- Bern University Hospital, Inselspital, Bern, Switzerland
| | - C Hamm
- Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany
| | - P Gabriel Steg
- Bichat Hospital, University Paris-Diderot, INSERM-UMR1148, FACT French Alliance for Cardiovascular T, Paris, France
| | - Y Onuma
- National University of Ireland Galway, Galway, Ireland
| | - P Serruys
- National University of Ireland Galway, Galway, Ireland
| | | |
Collapse
|
4
|
Hara H, Takahashi K, Klaveren D, Ono M, Kawashima H, Kappetein P, Mohr F, Mack M, Holmes D, Morice M, Davierwala P, Head S, Thuijs D, Onuma Y, Serruys P. Ten-year all-cause death after percutaneous or surgical revascularization for men and women with multivessel or left main coronary artery disease: insights from the SYNTAX extended survival study. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2497] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
In patients with complex coronary artery disease (CAD), women favored coronary artery bypass grafting surgery (CABG) compared to percutaneous coronary intervention (PCI) at 5 years in the SYNTAX trial, whereas mortality rates after PCI and CABG were not different in men. On the other hand, poor outcomes of women undergoing PCI were not observed in the PRECOMBAT and BEST trials.
The long-term optimal revascularization strategy according to gender has not been fully evaluated.
Purpose
In the SYNTAX Extended Survival (SYNTAXES) study, no significant difference existed in all-cause death between PCI and CABG at 10 years. This study aimed to assess treatment effect of PCI and CABG for 10-year all-cause death according to gender.
Methods
The SYNTAXES study evaluated vital status up to 10 years in 1,800 patients with de novo three-vessel disease (3VD) and/or left main coronary artery disease (LMCAD) randomized to treatment with CABG or PCI in the SYNTAX trial, and the pre-specified primary endpoint was all-cause death at 10 years. In this prespecified analysis, all-cause death at 10 years according to gender in patients undergoing PCI or CABG was evaluated.
Results
Of 1800 patients, 402 (22.3%) were women and 1398 (77.7%) were men. In women, the rate of mortality was significantly higher in the PCI arm at 5 years than in the CABG arm (19.3% vs. 10.3%; Log-rank p=0.010, Figure A), but the rates of mortality were not different at 10 years between the PCI and CABG arms (33.0% vs. 32.5%; Log-rank p=0.600, Figure A). In men, the mortality rate tended to be higher in the PCI arm at 10 years than in the CABG arm (27.0% vs. 22.5%; Log-rank p=0.082, Figure B), although the mortality rates were not different at 5 years between the PCI and CABG arms (12.4% vs. 12.3%; Log-rank p=0.957, Figure B).
Conclusion
The efficacy of CABG observed at 5 years disappeared at 10 years in women, whereas the efficacy of CABG became apparent after 5 years in men.
Figure 1
Funding Acknowledgement
Type of funding source: Public Institution(s). Main funding source(s): Erasmus University Medical Centre, Rotterdam, Netherlands, reference: MEC-2016-716
Collapse
Affiliation(s)
- H Hara
- Amsterdam UMC - Location Academic Medical Center, Amsterdam, Netherlands (The)
| | - K Takahashi
- Amsterdam UMC - Location Academic Medical Center, Amsterdam, Netherlands (The)
| | - D Klaveren
- Erasmus University Medical Centre, Rotterdam, Netherlands (The)
| | - M Ono
- Amsterdam UMC - Location Academic Medical Center, Amsterdam, Netherlands (The)
| | - H Kawashima
- Amsterdam UMC - Location Academic Medical Center, Amsterdam, Netherlands (The)
| | - P Kappetein
- Erasmus University Medical Centre, Rotterdam, Netherlands (The)
| | - F Mohr
- Heart Center of Leipzig, Leipzig, Germany
| | - M Mack
- Baylor University Medical Center, Dallas, United States of America
| | - D Holmes
- Mayo Clinic, Rochester, United States of America
| | - M Morice
- Jacques Cartier Private Hospital, Massy, France
| | | | - S Head
- Erasmus University Medical Centre, Rotterdam, Netherlands (The)
| | - D Thuijs
- Erasmus University Medical Centre, Rotterdam, Netherlands (The)
| | - Y Onuma
- National University of Ireland, Galway, Ireland
| | - P Serruys
- National University of Ireland, Galway, Ireland
| |
Collapse
|
5
|
Gao C, Wang R, Takahashi K, Kawashima H, Van Geuns R, Onuma Y, Morice M, Davierwala P, Holmes D, Mack M, Mohr F, Kappetein A, Head S, Thuijs D, Serruys P. Treatment of complex coronary artery disease in patients with diabetes mellitus and chronic kidney disease: 10-year results comparing outcomes of CABG and PCI in the SYNTAXES trial. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2520] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The SYNTAX Extended Survival (SYNTAXES) study is an investigator-driven extension of follow-up of the SYNTAX trial, which was a non-inferiority trial that compared percutaneous coronary intervention (PCI) using first-generation paclitaxel-eluting stents with coronary artery bypass grafting (CABG) in patients with de-novo three-vessel and left main coronary artery disease. The SYNTAXES study is the first randomized trial that reported the complete 10-year data on all-cause death in patients with complex coronary artery disease.
Purpose
Patients with coronary artery disease (CAD) and concomitant diabetes mellitus (DM) or chronic kidney disease (CKD) are more susceptible to major adverse cardiovascular and cerebrovascular events. However, to date, the long-term prognosis and which revascularization strategy was associated with better clinical outcomes for patients with complex coronary artery disease and concomitant with DM and CKD have not been documented.
Methods
In this sub-analysis of the SYNTAXES trial, a total of 1,638 patients were classified into four subgroups according to the DM and CKD status: DM−/CKD− (n=999, 60.1%), DM+/CKD− (n=323, 19.7%), DM−/CKD+ (n=231, 14.1%), and DM+/CKD+ (n=85, 5.2%). The treatment effects of PCI and CABG were analyzed in each subgroup. The primary endpoint was all-cause death at 10 years.
Results
Compared with the DM−/CKD− patients, patients with DM+/CKD+ were older, more often had a history of stroke, hypertension, heart failure, and were more frequently presented with total occlusion, bifurcation lesion and three-vessel disease. At 10 years, patients with DM+/CKD+ had a 3.94-fold higher incidence of all-cause mortality compared with DM−/CKD− individuals (54.1% versus 18.9%, 95% CI [2.85–5.44]). Patients with DM−/CKD+ (38.1%, HR 2.36; 95% CI [1.83–5.44]) or DM+/CKD− (28.2%, HR 1.61; 95% CI [1.26–2.07]) had intermediate risk profile. For DM+/CKD+ patients, compared with PCI, those who underwent CABG were associated with lower incidence of all-cause mortality (64.3% versus 44.2%, adjusted HR 0.52; 95% CI [0.27–0.99], p=0.047, pinteraction=0.443). The number of needed-to-treat to reduce mortality for CABG was 12.
Conclusion
In the SYNTAX population, patients with DM and CKD are at markedly increased risk of long-term mortality rate compared with patients one or neither of these risk factors. For patients with both comorbidities, CABG was associated with better clinical outcome compared with PCI. These findings should be interpreted as hypothesis-generating.
Figure 1. Kaplan-Meier curves showing the clinical events according to treatment and DM/CKD status.
Funding Acknowledgement
Type of funding source: Private company. Main funding source(s): Boston Scientific Corporation
Collapse
Affiliation(s)
- C Gao
- Xijing Hospital of the Fourth Military Medical University, Xi'an, China
| | - R.T Wang
- Xijing Hospital of the Fourth Military Medical University, Xi'an, China
| | | | - H Kawashima
- National University of Ireland, Galway, Ireland
| | - R.J Van Geuns
- University Medical Center St Radboud (UMCN), Nijmegen, Netherlands (The)
| | - Y Onuma
- National University of Ireland, Galway, Ireland
| | - M.C Morice
- ICPS Ramsay-Generale de Sante, Massy, France
| | | | - D Holmes
- Mayo Clinic, Rochester, United States of America
| | - M Mack
- Baylor Scott & White Health, Dallas, United States of America
| | - F Mohr
- Heart Center of Leipzig, Leipzig, Germany
| | - A Kappetein
- Erasmus University Medical Centre, Rotterdam, Netherlands (The)
| | - S Head
- Erasmus University Medical Centre, Rotterdam, Netherlands (The)
| | - D Thuijs
- Erasmus University Medical Centre, Rotterdam, Netherlands (The)
| | - P.W Serruys
- National University of Ireland, Galway, Ireland
| |
Collapse
|
6
|
Watanabe Y, Nara Y, Hioki H, Kawashima H, Kataoka A, Nakashima M, Nishihata Y, Hayashida K, Yamamoto M, Tanaka J, Mizutani K, Jujo K, Nakazawa G, Izumo M, Kozuma K. Short-term effects of low-dose tolvaptan in acute decompensated heart failure patients with severe aortic stenosis: the LOHAS registry. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Tolvaptan exerts potent diuretic effects in heart failure patients without hemodynamic instability. Nonetheless, its clinical efficacy for acute decompensated heart failure (ADHF) due to severe aortic stenosis (AS) remains unclear. This study aimed to evaluate the short-term effects of tolvaptan in ADHF patients with severe AS.
Methods
The LOw-Dose Tolvaptan (7.5 mg) in Decompensated Heart Failure Patients with Severe Aortic Stenosis (LOHAS) registry is a multicenter (7 centers) prospective registry that assessed the short-term effects of tolvaptan in subjects hospitalized for ADHF with severe AS. A total of 59 subjects were enrolled between September 2014 and December 2017. The primary endpoints were changes in body weight and fluid balance measured daily from baseline up to 4 days.
Results
The median [interquartile range] patient age and aortic valve area were 85.0 [81.0–89.0] years and 0.58 [0.42–0.74] cm2, respectively. Body weight continuously decreased, and fluid balance was maintained from baseline to day 4 (p<0.001, p=0.194, respectively). Median serum B-type natriuretic peptide concentration significantly decreased from 910.5 to 740.0 pg/mL by day 4 (p=0.002). However, systolic blood pressure and heart rate were non-significantly changed (p=0.250, p=0.656, respectively). Hypernatremia (>150 mEq/L) and worsening renal function occurred in 2 (3.4%) and 4 (6.8%) patients, respectively.
Conclusions
Short-term treatment with low-dose tolvaptan is safe and effective, providing stable hemodynamic parameters in patients with ADHF and severe AS.
Funding Acknowledgement
Type of funding source: Private company. Main funding source(s): This research was supported by Otsuka Pharmaceutical Co., Ltd.
Collapse
Affiliation(s)
- Y Watanabe
- Teikyo University Hospital, Tokyo, Japan
| | - Y Nara
- Teikyo University Hospital, Tokyo, Japan
| | - H Hioki
- Teikyo University Hospital, Tokyo, Japan
| | | | - A Kataoka
- Teikyo University Hospital, Tokyo, Japan
| | | | - Y Nishihata
- St. Luke's International Hospital, Cardiology, Tokyo, Japan
| | | | - M Yamamoto
- Nagoya Heart Center, Cardiology, Nagoya, Japan
| | - J Tanaka
- Tokyo Metropolitan Geriatric Hospital, Cardiology, Tokyo, Japan
| | - K Mizutani
- Osaka City University Graduate School of Medicine, Cardiology, Osaka, Japan
| | - K Jujo
- Nishiarai Heart Center, Cardiology, Tokyo, Japan
| | - G Nakazawa
- Tokai University School of Medicine, Cardiology, Kanagawa, Japan
| | - M Izumo
- St. Marianna University School of Medicine, Cardiology, Kawasaki, Japan
| | - K Kozuma
- Teikyo University Hospital, Tokyo, Japan
| |
Collapse
|
7
|
Hosokawa T, Yamada Y, Tanami Y, Sato Y, Tanaka Y, Kawashima H, Oguma E. Complications after Surgical Correction of Anorectal Malformations. Hong Kong Journal of Radiology 2020. [DOI: 10.12809/hkjr2017047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Affiliation(s)
- T Hosokawa
- Department of Radiology, Saitama Children’s Medical Center, Saitama, Japan
| | - Y Yamada
- Department of Radiology, Keio University School of Medicine, Tokyo, Japan
| | - Y Tanami
- Department of Radiology, Saitama Children’s Medical Center, Saitama, Japan
| | - Y Sato
- Department of Radiology, Saitama Children’s Medical Center, Saitama, Japan
| | - Y Tanaka
- Department of Pediatric Surgery, Nagoya University Graduate School of Medicine, Saitama, Japan
| | - H Kawashima
- Department of Surgery, Saitama Children’s Medical Center, Saitama, Japan
| | - E Oguma
- Department of Radiology, Saitama Children’s Medical Center, Saitama, Japan
| |
Collapse
|
8
|
Kawashima H, Zocca P, Buiten RA, Smits PC, Onuma Y, Wykrzykowska JJ, de Winter RJ, von Birgelen C, Serruys PW. The 2010s in clinical drug-eluting stent and bioresorbable scaffold research: a Dutch perspective. Neth Heart J 2020; 28:78-87. [PMID: 32780336 PMCID: PMC7419418 DOI: 10.1007/s12471-020-01442-w] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Dutch researchers were among the first to perform clinical studies in bare metal coronary stents, the use of which was initially limited by a high incidence of in-stent restenosis. This problem was greatly solved by the introduction of drug-eluting stents (DES). Nevertheless, enthusiasm about first-generation DES was subdued by discussions about a higher risk of very-late stent thrombosis and mortality, which stimulated the development, refinement, and rapid adoption of new DES with more biocompatible durable polymer coatings, biodegradable polymer coatings, or no coating at all. In terms of clinical DES research, the 2010s were characterised by numerous large-scale randomised trials in all-comers and patients with minimal exclusion criteria. Bioresorbable scaffolds (BRS) were developed and investigated. The Igaki-Tamai scaffold without drug elution was clinically tested in the Netherlands in 1999, followed by an everolimus-eluting BRS (Absorb) which showed favourable imaging and clinical results. Afterwards, multiple clinical trials comparing Absorb and its metallic counterpart were performed, revealing an increased rate of scaffold thrombosis during follow-up. Based on these studies, the commercialisation of the device was subsequently halted. Novel technologies are being developed to overcome shortcomings of first-generation BRS. In this narrative review, we look back on numerous devices and on the DES and BRS trials reported by Dutch researchers.
Collapse
Affiliation(s)
- H Kawashima
- Department of Clinical and Experimental Cardiology, Heart Center, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.,Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland
| | - P Zocca
- Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, The Netherlands
| | - R A Buiten
- Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, The Netherlands.,Health Technology and Services Research, Faculty of Behavioural Management and Social Sciences, Technical Medical Centre, University of Twente, Enschede, The Netherlands
| | - P C Smits
- Department of Cardiology, Maasstad Hospital, Rotterdam, The Netherlands
| | - Y Onuma
- Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland
| | - J J Wykrzykowska
- Department of Clinical and Experimental Cardiology, Heart Center, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - R J de Winter
- Department of Clinical and Experimental Cardiology, Heart Center, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - C von Birgelen
- Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, The Netherlands.,Health Technology and Services Research, Faculty of Behavioural Management and Social Sciences, Technical Medical Centre, University of Twente, Enschede, The Netherlands
| | - P W Serruys
- Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland. .,Imperial College London, London, UK.
| |
Collapse
|
9
|
Tanaka H, Yamamoto H, Kawashima H. CBT-I for co-mobid insomnia and sleep apnea. Sleep Med 2019. [DOI: 10.1016/j.sleep.2019.11.1045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
10
|
Hibino T, Ichikawa K, Fang Y, Ito S, Kawashima H, Bae KT. Determination of contrast medium dose for hepatic CT enhancement with improved body size dependency using a non-linear analysis based on pharmacokinetic principles. Clin Radiol 2019; 75:238.e11-238.e19. [PMID: 31679815 DOI: 10.1016/j.crad.2019.09.140] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2019] [Accepted: 09/11/2019] [Indexed: 10/25/2022]
Abstract
AIM To propose a pharmacokinetic non-linear analysis method to determine contrast medium (CM) dose for computed tomography (CT) hepatic enhancement to improve body size dependency and validate the proposed CM dose determination method through a clinical study. MATERIALS AND METHODS Enhancement data of 105 patients who underwent hepatic dynamic CT with a fixed CM dose were analysed. From the analysis results, CM doses as a function of each of four body size indices (body weight [BW], lean body weight [LBW], blood volume [BV], and body surface area [BSA]) for achieving improved body size dependency were determined (proposed method), and the body size dependencies were simulated using the enhancement data from 105 patients. The proposed method was validated with a two-arm clinical study on BW. Body size dependency was evaluated using p-value of correlation coefficient between Body size indices and enhancements (p<0.05: significant dependency) and mean absolute error (MAE). RESULTS The simulation showed that significant body size dependencies not considered by the conventional method can be improved by the proposed method. MAEs of BW, LBW, and BV were also significantly reduced (p<0.05). The clinical study with BW demonstrated a similar improvement to that in the simulation result. MAE was also significantly reduced (p<0.001). CONCLUSION The proposed method demonstrated more improved BW, LBW, and BV dependence compared to the conventional method. Through the two-arm clinical study, the proposed method using BW only, without height information, is a suitable index for improving body size dependency.
Collapse
Affiliation(s)
- T Hibino
- Department of Radiological Technology, Daiyukai General Hospital, 1-9-9 Sakura, Ichinomiya, Aichi, 491-8551, Japan; Graduate School of Medical Science, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa, Ishikawa, 920-0942, Japan
| | - K Ichikawa
- Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa, Ishikawa, 920-0942, Japan.
| | - Y Fang
- MIMOSA Diagnostics, 1 Yonge St, Toronto, M5E1E5, Canada
| | - S Ito
- Department of Radiology, Daiyukai General Hospital, 1-9-9 Sakura, Ichinomiya, Aichi, 491-8551, Japan
| | - H Kawashima
- Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa, Ishikawa, 920-0942, Japan
| | - K T Bae
- Department of Radiology, University of Pittsburgh School of Medicine, 3362 Fifth Ave, Pittsburgh, PA, 15213, USA
| |
Collapse
|
11
|
Mitsui M, Kataoka A, Nara Y, Nagura F, Kawashima H, Hioki H, Nakashima M, Watanabe Y, Yokoyama N, Kozuma K. P2621Clinical safety and efficacy of tolvaptan for acute phase therapy in patients with low-flow severe aortic stenosis. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0944] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Conventional diuretic therapy for low-flow (LF) severe aortic stenosis (SAS) often has an inadequate effect or causes hemodynamic instability. Tolvaptan is used for acute heart failure in addition to conventional diuretics in Japan, and it does not cause intravascular dehydration.
Purpose
This study aimed to retrospectively investigate the safety and efficacy of tolvaptan in the acute phase patients with SAS and compared LF-SAS with normal-flow (NF) SAS.
Methods
56 consecutive SAS patients are analyzed. The primary endpoints were adverse clinical events (death, worsening heart failure, worsening renal failure, fatal arrhythmia, cardiogenic or hypovolemic shock, and use of inotropic agents) and the volume of urine and fluid balance within 48 hours of tolvaptan administration (Figure).
Results
Among 56 patients, 16 had LF-SAS (29%), and 40 had NF-SAS (71%). Severe adverse clinical events were not observed 48 hours after tolvaptan administration. In both groups, the urine volume significantly increased after tolvaptan administration in comparison to 24 hours before tolvaptan administration (both, p<0.01). There were no changes in the urine volume during the initial 24 and 48 hours. In the LF-SAS group, tolvaptan resulted in a significant decrease in fluid balance during the initial 24 and 48 hours compared to 24 hours before tolvaptan administration (p<0.05).
Treatment and data collection protocols
Conclusion
Adding tolvaptan to conventional treatment leads to an increase in urine output and a decreased fluid balance without hemodynamic instability in patients with LF-SAS.
Acknowledgement/Funding
None
Collapse
Affiliation(s)
| | | | - Y Nara
- Teikyo University, Tokyo, Japan
| | | | | | - H Hioki
- Teikyo University, Tokyo, Japan
| | | | | | | | | |
Collapse
|
12
|
Oike N, Kawashima H, Ogose A, Hatano H, Ariizumi T, Kaidu M, Aoyama H, Endo N. Long-term outcomes of an extracorporeal irradiated autograft for limb salvage operations in musculoskeletal tumours. Bone Joint J 2019; 101-B:1151-1159. [DOI: 10.1302/0301-620x.101b9.bjj-2019-0090.r1] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Aims We analyzed the long-term outcomes of patients observed over ten years after resection en bloc and reconstruction with extracorporeal irradiated autografts Patients and Methods This retrospective study included 27 patients who underwent resection en bloc and reimplantation of an extracorporeal irradiated autograft. The mean patient age and follow-up period were 31.7 years (9 to 59) and 16.6 years (10.3 to 24.3), respectively. The most common diagnosis was osteosarcoma (n = 10), followed by chondrosarcoma (n = 6). The femur (n = 13) was the most frequently involved site, followed by the tibia (n = 7). There were inlay grafts in five patients, intercalary grafts in 15 patients, and osteoarticular grafts in seven patients. Functional outcome was evaluated with the Musculoskeletal Tumor Society (MSTS) scoring system. Results There were no recurrences in the irradiated autograft and the autograft survived in 24 patients (88.9%). Major complications included nonunion (n = 9), subchondral bone collapse (n = 4), and deep infection (n = 4). Although 34 revision procedures were performed, 25 (73.5%) and four (11.8%) of these were performed less than five years and ten years after the initial surgery, respectively. The mean MSTS score at the last follow-up was 84.3% (33% to 100%). Conclusion Considering long-term outcomes, extracorporeal irradiated autograft is an effective method of reconstruction for malignant musculoskeletal tumours Cite this article: Bone Joint J 2019;101-B:1151–1159
Collapse
Affiliation(s)
- N. Oike
- Division of Orthopaedic Surgery, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
| | - H. Kawashima
- Division of Orthopaedic Surgery, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
| | - A. Ogose
- Division of Orthopaedic Surgery, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
- Department of Orthopaedic Surgery, Uonuma Kikan Hospital, Niigata, Japan
| | - H. Hatano
- Department of Orthopaedic Surgery, Niigata Cancer Hospital, Niigata, Japan
| | - T. Ariizumi
- Division of Orthopaedic Surgery, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
| | - M. Kaidu
- Department of Radiology and Radiation Oncology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
| | - H. Aoyama
- Department of Radiology and Radiation Oncology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
| | - N. Endo
- Division of Orthopaedic Surgery, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
| |
Collapse
|
13
|
Tobita R, Egusa C, Maeda T, Abe N, Sakai N, Suzuki S, Kawashima H, Hokibara S, Ko J, Okubo Y. A novel CARD14 variant, homozygous c.526G>C (p.Asp176His), in an adolescent Japanese patient with palmoplantar pustulosis. Clin Exp Dermatol 2019; 44:694-696. [PMID: 30723930 DOI: 10.1111/ced.13926] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/17/2018] [Indexed: 11/30/2022]
Affiliation(s)
- R Tobita
- Department of Dermatology, Tokyo Medical University, Tokyo, Japan
| | - C Egusa
- Department of Dermatology, Tokyo Medical University, Tokyo, Japan
| | - T Maeda
- Department of Dermatology, Tokyo Medical University, Tokyo, Japan
| | - N Abe
- Department of Dermatology, Tokyo Medical University, Tokyo, Japan
| | - N Sakai
- Department of Dermatology, Tokyo Medical University, Tokyo, Japan
| | - S Suzuki
- Department of Pediatrics, Tokyo Medical University, Tokyo, Japan
| | - H Kawashima
- Department of Pediatrics, Tokyo Medical University, Tokyo, Japan
| | - S Hokibara
- Department of Pediatrics, Kohu City Hospital, Yamanashi, Japan
| | - J Ko
- Department of Otorhinolaryngology, Kohu City Hospital, Yamanashi, Japan
| | - Y Okubo
- Department of Dermatology, Tokyo Medical University, Tokyo, Japan
| |
Collapse
|
14
|
Abstract
BACKGROUND The efficacy of macrolide treatment on gastrointestinal motility and acquirement of feeding tolerance in extremely low birth weight (ELBW) infants are controversial. This study aimed to evaluate clinical effects of parenterally administered erythromycin (EM) and clarithromycin (CAM) on gastrointestinal motility in ELBW infants. METHODS ELBW infants treated in Tokyo Medical University Hospital were retrospectively studied. Several outcomes of ELBW infants treated with EM or CAM were compared with those recognized before initiation of the medication, as well as with those of patients with no macrolide treatment. The primary outcomes included average gastric residual volume that was evaluated 3 hours after enteral feeding. Secondary outcomes were the number of patients who developed feeding intolerance, stool frequency, and other adverse events, such as respiratory comorbidities and pyloric stenosis. RESULTS Among a total of 53 infants, 20 and 13 were treated with EM and CAM, respectively, whereas 20 infants were not administered macrolides. The gastric residual volume was significantly decreased after initiation of medication compared with before medication in the EM group, whereas that of the untreated group showed no change. When the EM and CAM groups were combined, the gastric residual volume was also significantly decreased after treatment compared with before treatment. An increase in stool frequency and pyloric stenosis were not observed in the groups. CONCLUSION EM might be effective for acquiring feeding tolerance in ELBW infants. A future prospective study with a larger population is required to determine the efficacy of CAM.
Collapse
Affiliation(s)
- J Nakajima
- Department of Pediatrics, Tokyo Medical University, Tokyo, Japan
- Department Neonatology, Kameda Medical Center, Chiba, Japan
| | - D Sunohara
- Department of Pediatrics, Tokyo Medical University, Tokyo, Japan
| | - H Kawashima
- Department of Pediatrics, Tokyo Medical University, Tokyo, Japan
| |
Collapse
|
15
|
Otsuki H, Jujo K, Tanaka K, Okai I, Dohi T, Okazaki S, Kawashima H, Nakashima M, Nara Y, Kyono H, Yamaguchi J, Miyauchi K, Daida H, Kozuma K, Hagiwara N. P3587Gender difference in long-term clinical outcomes after rotational atherectomy in severely calcified coronary stenoses - From J2T multicenter registry. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p3587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- H Otsuki
- Tokyo Women's Medical University, Department of Cardiology, Tokyo, Japan
| | - K Jujo
- Tokyo Women's Medical University, Department of Cardiology, Tokyo, Japan
| | - K Tanaka
- Tokyo Women's Medical University, Department of Cardiology, Tokyo, Japan
| | - I Okai
- Juntendo University, Cardiology, Tokyo, Japan
| | - T Dohi
- Juntendo University, Cardiology, Tokyo, Japan
| | - S Okazaki
- Juntendo University, Cardiology, Tokyo, Japan
| | | | | | - Y Nara
- Teikyo University, Cardiology, Tokyo, Japan
| | - H Kyono
- Teikyo University, Cardiology, Tokyo, Japan
| | - J Yamaguchi
- Tokyo Women's Medical University, Department of Cardiology, Tokyo, Japan
| | - K Miyauchi
- Juntendo University, Cardiology, Tokyo, Japan
| | - H Daida
- Juntendo University, Cardiology, Tokyo, Japan
| | - K Kozuma
- Teikyo University, Cardiology, Tokyo, Japan
| | - N Hagiwara
- Tokyo Women's Medical University, Department of Cardiology, Tokyo, Japan
| | | |
Collapse
|
16
|
Jujo K, Tanaka K, Otsuki H, Okai I, Nakashima M, Dohi T, Okazaki S, Kawashima H, Nara Y, Kyono H, Yamaguchi J, Miyauchi K, Daida H, Kozuma K, Hagiwara N. P501Prediction of 3-year mortality after rotational atherectomy in severely calcified coronary artery. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx501.p501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Kyono H, Nakashima M, Takamura S, Nakaya H, Nishide S, Nara Y, Sasaki K, Katayama T, Nagura F, Kawashima H, Hioki H, Watanabe Y, Konno K, Yokoyama N, Kozuma K. P4289The impact of transient slow flow/no-reflow during rotational atherectomy on clinical outcomes. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p4289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
18
|
Jujo K, Otsuki H, Tanaka K, Okai I, Nakashima M, Dohi T, Okazaki S, Kawashima H, Nara Y, Kyono H, Yamaguchi J, Miyauchi K, Daida H, Kozuma K, Hagiwara N. P6452Predictors for long-term cardiovascular death after rotational atherectomy in patients with regular hemodialysis - from J2T multicenter registry -. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p6452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- K. Jujo
- Tokyo Women's Medical University, Department of Cardiology, Tokyo, Japan
| | - H. Otsuki
- Tokyo Women's Medical University, Department of Cardiology, Tokyo, Japan
| | - K. Tanaka
- Tokyo Women's Medical University, Department of Cardiology, Tokyo, Japan
| | - I. Okai
- Juntendo University, Department of Cardiology, Tokyo, Japan
| | - M. Nakashima
- Teikyo University, Department of Cardiology, Tokyo, Japan
| | - T. Dohi
- Juntendo University, Department of Cardiology, Tokyo, Japan
| | - S. Okazaki
- Juntendo University, Department of Cardiology, Tokyo, Japan
| | - H. Kawashima
- Teikyo University, Department of Cardiology, Tokyo, Japan
| | - Y. Nara
- Teikyo University, Department of Cardiology, Tokyo, Japan
| | - H. Kyono
- Teikyo University, Department of Cardiology, Tokyo, Japan
| | - J. Yamaguchi
- Tokyo Women's Medical University, Department of Cardiology, Tokyo, Japan
| | - K. Miyauchi
- Juntendo University, Department of Cardiology, Tokyo, Japan
| | - H. Daida
- Juntendo University, Department of Cardiology, Tokyo, Japan
| | - K. Kozuma
- Teikyo University, Department of Cardiology, Tokyo, Japan
| | - N. Hagiwara
- Tokyo Women's Medical University, Department of Cardiology, Tokyo, Japan
| | | |
Collapse
|
19
|
|
20
|
Kasai S, Kamiya K, Shinohara K, Kawashima H, Ogawa H, Uehara K, Miura Y, Okano F, Suzuki S, Hoshino K, Tsuzuki K, Sato M, Oasa K, Kusama Y, Yamauchi T, Nagashima Y, Ida K, Hidekuma S, Ido T, Hamada Y, Nishizawa A, Kawasumi Y, Uesugi Y, Okajima S, Kawahata K, Ejiri A, Amemiya H, Sadamoto Y. Plasma Diagnostics in JFT-2M. Fusion Science and Technology 2017. [DOI: 10.13182/fst06-a1097] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- S. Kasai
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, Naka-shi, Ibaraki-ken 311-0193, Japan
| | - K. Kamiya
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, Naka-shi, Ibaraki-ken 311-0193, Japan
| | - K. Shinohara
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, Naka-shi, Ibaraki-ken 311-0193, Japan
| | - H. Kawashima
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, Naka-shi, Ibaraki-ken 311-0193, Japan
| | - H. Ogawa
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, Naka-shi, Ibaraki-ken 311-0193, Japan
| | - K. Uehara
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, Naka-shi, Ibaraki-ken 311-0193, Japan
| | - Y. Miura
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, Naka-shi, Ibaraki-ken 311-0193, Japan
| | - F. Okano
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, Naka-shi, Ibaraki-ken 311-0193, Japan
| | - S. Suzuki
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, Naka-shi, Ibaraki-ken 311-0193, Japan
| | - K. Hoshino
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, Naka-shi, Ibaraki-ken 311-0193, Japan
| | - K. Tsuzuki
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, Naka-shi, Ibaraki-ken 311-0193, Japan
| | - M. Sato
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, Naka-shi, Ibaraki-ken 311-0193, Japan
| | - K. Oasa
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, Naka-shi, Ibaraki-ken 311-0193, Japan
| | - Y. Kusama
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, Naka-shi, Ibaraki-ken 311-0193, Japan
| | - T. Yamauchi
- Japan Atomic Energy Research Institute, Kansai Research Establishment, Tokai-mura, Naka-gun Ibaraki-ken 319-1195, Japan
| | - Y. Nagashima
- Kyushu University, Research Institute for Applied Mechanics, Kasuga-shi, Fukuoka-ken 816-8580, Japan
| | - K. Ida
- National Institute for Fusion Science, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Hidekuma
- National Institute for Fusion Science, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Ido
- National Institute for Fusion Science, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Hamada
- National Institute for Fusion Science, Toki-shi, Gifu-ken 509-5292, Japan
| | - A. Nishizawa
- National Institute for Fusion Science, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Kawasumi
- National Institute for Fusion Science, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Uesugi
- Kanazawa University, Kanazawa-shi, Ishikawa-ken 920-8667, Japan
| | - S. Okajima
- Chubu University, College of Engineering, Kasugai-shi, Aichi-ken 487-8501, Japan
| | - K. Kawahata
- Kanazawa University, Kanazawa-shi, Ishikawa-ken 920-8667, Japan
| | - A. Ejiri
- The University of Tokyo, Graduate School of Frontier Sciences, Kashiwa-shi, Chiba-ken 277-8561, Japan
| | - H. Amemiya
- Chuo University, The Faculty of Science and Engineering, Bunkyo-ku, Tokyo-to 112-8551, Japan
| | - Y. Sadamoto
- Joetsu University of Education, Joetsu-shi, Niigata-ken 943-8512, Japan
| |
Collapse
|
21
|
Yamamoto M, Shibata T, Tsuzuki K, Sato M, Kimura H, Okano F, Kawashima H, Suzuki S, Shinohara K, Urata K. Engineering Design, Installation, and Conditioning of Ferritic Steel Plates/Wall for AMTEX in JFT-2M. Fusion Science and Technology 2017. [DOI: 10.13182/fst06-a1098] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- M. Yamamoto
- Japan Atomic Energy Research Institute, Tokai-mura, Naka-gun, Ibaraki-ken 319-1195, Japan
| | - T. Shibata
- Japan Atomic Energy Research Institute, Tokai-mura, Naka-gun, Ibaraki-ken 319-1195, Japan
| | - K. Tsuzuki
- Japan Atomic Energy Research Institute, Tokai-mura, Naka-gun, Ibaraki-ken 319-1195, Japan
| | - M. Sato
- Japan Atomic Energy Research Institute, Tokai-mura, Naka-gun, Ibaraki-ken 319-1195, Japan
| | - H. Kimura
- Japan Atomic Energy Research Institute, Tokai-mura, Naka-gun, Ibaraki-ken 319-1195, Japan
| | - F. Okano
- Japan Atomic Energy Research Institute, Tokai-mura, Naka-gun, Ibaraki-ken 319-1195, Japan
| | - H. Kawashima
- Japan Atomic Energy Research Institute, Tokai-mura, Naka-gun, Ibaraki-ken 319-1195, Japan
| | - S. Suzuki
- Japan Atomic Energy Research Institute, Tokai-mura, Naka-gun, Ibaraki-ken 319-1195, Japan
| | - K. Shinohara
- Japan Atomic Energy Research Institute, Tokai-mura, Naka-gun, Ibaraki-ken 319-1195, Japan
| | - K. Urata
- Mitsubishi Heavy Industries, Ltd., Office Tower Z 1-3-12, Harumi, Chuo-ku Tokyo 140-6125, Japan
| | | |
Collapse
|
22
|
Tsuzuki K, Kimura H, Kusama Y, Sato M, Kawashima H, Kamiya K, Shinohara K, Ogawa H, Uehara K, Kurita G, Kasai S, Hoshino K, Isei N, Miura Y, Yamamoto M, Kikuchi K, Shibata T, Bakhtiari M, Hino T, Hirohata Y, Yamauchi Y, Yamaguchi K, Tsutsui H, Shimada R, Amemiya H, Nagashima Y, Ido T, Hamada Y. Characteristics of Plasma Operation with the Ferritic inside Wall and Its Compatibility with High-Performance Plasmas in JFT-2M. Fusion Science and Technology 2017. [DOI: 10.13182/fst06-a1095] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- K. Tsuzuki
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-shi, Inaraki 319-0193, Japan
| | - H. Kimura
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-shi, Inaraki 319-0193, Japan
| | - Y. Kusama
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-shi, Inaraki 319-0193, Japan
| | - M. Sato
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-shi, Inaraki 319-0193, Japan
| | - H. Kawashima
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-shi, Inaraki 319-0193, Japan
| | - K. Kamiya
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-shi, Inaraki 319-0193, Japan
| | - K. Shinohara
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-shi, Inaraki 319-0193, Japan
| | - H. Ogawa
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-shi, Inaraki 319-0193, Japan
| | - K. Uehara
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-shi, Inaraki 319-0193, Japan
| | - G. Kurita
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-shi, Inaraki 319-0193, Japan
| | - S. Kasai
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-shi, Inaraki 319-0193, Japan
| | - K. Hoshino
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-shi, Inaraki 319-0193, Japan
| | - N. Isei
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-shi, Inaraki 319-0193, Japan
| | - Y. Miura
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-shi, Inaraki 319-0193, Japan
| | - M. Yamamoto
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-shi, Inaraki 319-0193, Japan
| | - K. Kikuchi
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-shi, Inaraki 319-0193, Japan
| | - T. Shibata
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-shi, Inaraki 319-0193, Japan
| | - M. Bakhtiari
- University of Wisconsin, Madison, Wisconsin 53706
| | - T. Hino
- Hokkaido University Sapporo, Hokkaido 060-8628, Japan
| | - Y. Hirohata
- Hokkaido University Sapporo, Hokkaido 060-8628, Japan
| | - Y. Yamauchi
- Hokkaido University Sapporo, Hokkaido 060-8628, Japan
| | - K. Yamaguchi
- Hokkaido University Sapporo, Hokkaido 060-8628, Japan
| | - H. Tsutsui
- Tokyo Institute of Technology, Meguro-ku Tokyo 152-8550, Japan
| | - R. Shimada
- Tokyo Institute of Technology, Meguro-ku Tokyo 152-8550, Japan
| | - H. Amemiya
- The Institute of Physical and Chemical Research, Wako, Saitama 351-0198, Japan
| | - Y. Nagashima
- National Institute for Fusion Science, Toki-shi 509-5292, Japan
| | - T. Ido
- National Institute for Fusion Science, Toki-shi 509-5292, Japan
| | - Y. Hamada
- National Institute for Fusion Science, Toki-shi 509-5292, Japan
| |
Collapse
|
23
|
Shinohara K, Sato M, Kawashima H, Tsuzuki K, Suzuki S, Urata K, Isei N, Tani T, Kikuchi K, Shibata T, Kimura H, Miura Y, Kusama Y, Yamamoto M. Ripple Reduction with Ferritic Insert in JFT-2M. Fusion Science and Technology 2017. [DOI: 10.13182/fst06-a1094] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- K. Shinohara
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, Naka, Ibaraki 311-0193, Japan
| | - M. Sato
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, Naka, Ibaraki 311-0193, Japan
| | - H. Kawashima
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, Naka, Ibaraki 311-0193, Japan
| | - K. Tsuzuki
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, Naka, Ibaraki 311-0193, Japan
| | - S. Suzuki
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, Naka, Ibaraki 311-0193, Japan
| | - K. Urata
- Mitsubishi Heavy Industries, Ltd., Kobe Shipyard and Machinery Works, 1-1-1 Wadasaki, Hyogo-ku Kobe, Hyogo 652-8585, Japan
| | - N. Isei
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, Naka, Ibaraki 311-0193, Japan
| | - T. Tani
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, Naka, Ibaraki 311-0193, Japan
| | - K. Kikuchi
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, Naka, Ibaraki 311-0193, Japan
| | - T. Shibata
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, Naka, Ibaraki 311-0193, Japan
| | - H. Kimura
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, Naka, Ibaraki 311-0193, Japan
| | - Y. Miura
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, Naka, Ibaraki 311-0193, Japan
| | - Y. Kusama
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, Naka, Ibaraki 311-0193, Japan
| | - M. Yamamoto
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, Naka, Ibaraki 311-0193, Japan
| | | |
Collapse
|
24
|
Motojima O, Yamada H, Komori A, Watanabe KY, Mutoh T, Takeiri Y, Ida K, Akiyama T, Asakura N, Ashikawa N, Chikaraishi H, Cooper WA, Emoto M, Fujita T, Fujiwara M, Funaba H, Goncharov P, Goto M, Hamada Y, Higashijima S, Hino T, Hoshino M, Ichimura M, Idei H, Ido T, Ikeda K, Imagawa S, Inagaki S, Isayama A, Isobe M, Itoh T, Itoh K, Kado S, Kalinina D, Kaneba T, Kaneko O, Kato D, Kato T, Kawahata K, Kawashima H, Kawazome H, Kobuchi T, Kondo K, Kubo S, Kumazawa R, Lyon JF, Maekawa R, Mase A, Masuzaki S, Mito T, Matsuoka K, Miura Y, Miyazawa J, More R, Morisaki T, Morita S, Murakami I, Murakami S, Mutoh S, Nagaoka K, Nagasaki K, Nagayama Y, Nakamura Y, Nakanishi H, Narihara K, Narushima Y, Nishimura H, Nishimura K, Nishiura M, Nishizawa A, Noda N, Notake T, Nozato H, Ohdachi S, Ohkubo K, Ohyabu N, Oyama N, Oka Y, Okada H, Osakabe M, Ozaki T, Peterson BJ, Sagara A, Saida T, Saito K, Sakakibara S, Sakamoto M, Sakamoto R, Sasao M, Sato K, Seki T, Shimozuma T, Shoji M, Sudo S, Takagi S, Takahashi Y, Takase Y, Takenaga H, Takeuchi N, Tamura N, Tanaka K, Tanaka M, Toi K, Takahata K, Tokuzawa T, Torii Y, Tsumori K, Watanabe F, Watanabe M, Watanabe T, Watari T, Yamada I, Yamada S, Yamaguchi T, Yamamoto S, Yamazaki K, Yanagi N, Yokoyama M, Yoshida N, Yoshimura S, Yoshimura Y, Yoshinuma M. Review on the Progress of the LHD Experiment. Fusion Science and Technology 2017. [DOI: 10.13182/fst04-a535] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- O. Motojima
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Yamada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - A. Komori
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Y. Watanabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Mutoh
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Takeiri
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Ida
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Akiyama
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Asakura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Ashikawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Chikaraishi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - W. A. Cooper
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Emoto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Fujita
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Fujiwara
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Funaba
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - P. Goncharov
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Goto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Hamada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Higashijima
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Hino
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Hoshino
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Ichimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Idei
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Ido
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Ikeda
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Imagawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Inagaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - A. Isayama
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Isobe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Itoh
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Itoh
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Kado
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - D. Kalinina
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Kaneba
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - O. Kaneko
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - D. Kato
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Kato
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Kawahata
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Kawashima
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Kawazome
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Kobuchi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Kondo
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Kubo
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - R. Kumazawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - J. F. Lyon
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - R. Maekawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - A. Mase
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Masuzaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Mito
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Matsuoka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Miura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - J. Miyazawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - R. More
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Morisaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Morita
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - I. Murakami
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Murakami
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Mutoh
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Nagaoka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Nagasaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Nagayama
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Nakamura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Nakanishi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Narihara
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Narushima
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Nishimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Nishimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Nishiura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - A. Nishizawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Noda
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Notake
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Nozato
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Ohdachi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Ohkubo
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Ohyabu
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Oyama
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Oka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Okada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Osakabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Ozaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - B. J. Peterson
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - A. Sagara
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Saida
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Saito
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Sakakibara
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Sakamoto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - R. Sakamoto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Sasao
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Sato
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Seki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Shimozuma
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Shoji
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Sudo
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Takagi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Takahashi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Takase
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Takenaga
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Takeuchi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Tamura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Tanaka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Tanaka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Toi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Takahata
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Tokuzawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Torii
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Tsumori
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - F. Watanabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Watanabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Watanabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Watari
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - I. Yamada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Yamada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Yamaguchi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Yamamoto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Yamazaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Yanagi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Yokoyama
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Yoshida
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Yoshimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Yoshimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Yoshinuma
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| |
Collapse
|
25
|
Takenaga H, Kawashima H, Nishio S, Tobita K. Study of Fueling Scenario and Particle Balance in a Fusion Reactor. Fusion Science and Technology 2017. [DOI: 10.13182/fst10-a9270] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- H. Takenaga
- Japan Atomic Energy Agency, 801-1 Mukouyama, Naka, Ibaraki 311-0193, Japan
| | - H. Kawashima
- Japan Atomic Energy Agency, 801-1 Mukouyama, Naka, Ibaraki 311-0193, Japan
| | - S. Nishio
- Japan Atomic Energy Agency, 801-1 Mukouyama, Naka, Ibaraki 311-0193, Japan
| | - K. Tobita
- Japan Atomic Energy Agency, 801-1 Mukouyama, Naka, Ibaraki 311-0193, Japan
| |
Collapse
|
26
|
Kawashima H, Mayama H, Nakamura Y, Fujii S. Hydrophobic polypyrroles synthesized by aqueous chemical oxidative polymerization and their use as light-responsive liquid marble stabilizers. Polym Chem 2017. [DOI: 10.1039/c7py00158d] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Hydrophobic polypyrroles doped with perfluoroalkyl dopants can function as a liquid marble stabilizer with photothermal properties.
Collapse
Affiliation(s)
- H. Kawashima
- Division of Applied Chemistry
- Graduate School of Engineering
- Osaka Institute of Technology
- Osaka 535-8585
- Japan
| | - H. Mayama
- Department of Chemistry
- Asahikawa Medical University
- Asahikawa 078-8510
- Japan
| | - Y. Nakamura
- Department of Applied Chemistry
- Faculty of Engineering
- Osaka Institute of Technology
- Osaka 535-8585
- Japan
| | - S. Fujii
- Department of Applied Chemistry
- Faculty of Engineering
- Osaka Institute of Technology
- Osaka 535-8585
- Japan
| |
Collapse
|
27
|
Suzuki M, Matsui O, Ueda F, Ougi T, Inoue D, Endo T, Kawashima H, Takemura A, Ichikawa K. MR Imaging of Hippocampal Sulcus Remnant: Age-Related Differences. Neuroradiol J 2016; 20:611-6. [DOI: 10.1177/197140090702000601] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2007] [Accepted: 09/16/2007] [Indexed: 11/15/2022] Open
Abstract
The hippocampal sulcus remnant (HSR) is often observed at the medial temporal lobe on MR images. In the present study, we made a retrospective assessment of the frequency and age-related differences in HSR in routine brain MR examinations of 1000 patients, 494 females and 506 males. Cases with one or several spots that were hypointense on T1-weighted and FLAIR images and hyperintense on T2-weighted images were defined as positive for HSR. Abnormal spots with the same intensity as cerebrospinal fluid were observed in 210 out of 506 males and in 193 out of 494 females. No significant sex-related differences were observed in the frequency of HSR. The HSR was seen more frequently with age in both males and females. Patients with hypertension had a significantly higher frequency of HSR.
Collapse
Affiliation(s)
- M. Suzuki
- Department of Quantum Medical Technology, Kanazawa University; Kanazawa, Ishikawa, Japan
| | - O. Matsui
- Department of Radiology, Graduate School of Medical Sciences, Kanazawa University; Kanazawa, Ishikawa, Japan
| | - F. Ueda
- Department of Radiology, Graduate School of Medical Sciences, Kanazawa University; Kanazawa, Ishikawa, Japan
| | - T. Ougi
- Department of Radiology, Graduate School of Medical Sciences, Kanazawa University; Kanazawa, Ishikawa, Japan
| | - D. Inoue
- Department of Radiology, Graduate School of Medical Sciences, Kanazawa University; Kanazawa, Ishikawa, Japan
| | - T. Endo
- Department of Radiology, Graduate School of Medical Sciences, Kanazawa University; Kanazawa, Ishikawa, Japan
| | - H. Kawashima
- Department of Radiology, Graduate School of Medical Sciences, Kanazawa University; Kanazawa, Ishikawa, Japan
| | - A. Takemura
- Department of Quantum Medical Technology, Kanazawa University; Kanazawa, Ishikawa, Japan
| | - K. Ichikawa
- Department of Quantum Medical Technology, Kanazawa University; Kanazawa, Ishikawa, Japan
| |
Collapse
|
28
|
Fujimura T, Fujimoto T, Kawashima H, Kira T, Hara R, Shimmyo N, Kobata Y, Kido A, Akai Y, Tanaka Y. AB0331 Early Improvement of Musculoskeletal Ultrasound Findings Can Predict Future Clinical Response To Certolizumab Pegol in Patients with Rheumatoid Arthritis. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.1909] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
29
|
Sagara Y, Sawaki M, Taira N, Saito T, Kashiwaba M, Iwata H, Kobayashi K, Nakayama T, Bando H, Mizuno T, Yamamoto Y, Tsuneizumi M, Takahashi M, Yamaguchi M, Kawashima H, Takashima T, Uemura Y, Hozumi Y, Sagawa N, Mukai H, Ohashi Y. Abstract P5-18-01: A randomized clinical trial of postoperative adjuvant therapy for elderly breast cancer patients: Conditions of obtaining informed consent and reasons for declining participation. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p5-18-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: There are few randomized clinical trials examining adjuvant treatment in elderly breast cancer patients. While obtaining informed consent is essential for participation in clinical studies, there is little information on the frequency of agreement to participate among elderly patients. Furthermore, elderly patients might have specific reasons to decline participation.
Patients and Method: The National Surgical Adjuvant Study of Breast Cancer 07 (N-SAS BC 07) is a randomized clinical trial in women over 70 years with HER2-positive primary breast cancer. The primary aim was to investigate the benefit of trastuzumab monotherapy compared with the combination of trastuzumab and chemotherapy. Key inclusion criteria were as follows: women between 70 and 80 years old with HER2-positive breast cancer; underwent curative operation; stage I to IIIA; with sufficient organ function. Patients were randomized to receive either trastuzumab plus chemotherapy or trastuzumab monotherapy. The primary endpoint was disease-free survival, and the secondary endpoints were overall survival, relapse-free survival, safety, health-related quality of life, and cost effectiveness (NCT01104935). It was not possible to predict the number of patients who would agree to participate. In order to comprehensively assess the effect of postoperative adjuvant therapy, we evaluated the reasons why eligible patients declined to participate. The patients were registered in a cohort study to prospectively evaluate the subsequent treatment options and prognosis (07-Cohort). This study examined the obtaining of informed consent for N-SAS BC 07 and the reasons for declining participation, and compared the clinicopathological backgrounds between the N-SAS BC 07 and 07-Cohort groups.
Results: 398 eligible patients have been recruited. Informed consent to participate in N-SAS BC 07 has been obtained from 275 patients (69%) and 123 patients (31%) who declined to participate in the RCT have been registered in the 07-Cohort. The common reasons to decline participation in the RCT were "cannot choose the treatment option (55%)", "refused chemotherapy (16%)", "wanted chemotherapy (9%)", "anxious about clinical studies (9%)" and "family opposition (8%)". The mean ages of the patients in N-SAS BC 07 and 07-Cohort were 73.9 and 74.6 years old, respectively. There were no differences in stage, surgical procedure, lymph node metastasis, or co-morbidities between the groups. ER-positive rate was higher in 07-Cohort group compared with N-SAS BC 07 group (53% vs. 37%, p=0.017, χ2 test).
Conclusion: While we expected the number of registrants to be small, since N-SAS BC 07 investigated whether elderly patients with HER2-positive breast cancer should undergo chemotherapy, almost 70% of the patients accepted informed consent. The most common reason to decline participation in N-SAS BC 07 was "cannot choose the treatment option" and the majority refused chemotherapy. Furthermore, ER-positivity was higher in the 07-Cohort group, which suggested that ER expression in the patients with HER2-positive breast cancer might influence their decision to participate in the study or to choose the treatment option.
Citation Format: Sagara Y, Sawaki M, Taira N, Saito T, Kashiwaba M, Iwata H, Kobayashi K, Nakayama T, Bando H, Mizuno T, Yamamoto Y, Tsuneizumi M, Takahashi M, Yamaguchi M, Kawashima H, Takashima T, Uemura Y, Hozumi Y, Sagawa N, Mukai H, Ohashi Y. A randomized clinical trial of postoperative adjuvant therapy for elderly breast cancer patients: Conditions of obtaining informed consent and reasons for declining participation. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-18-01.
Collapse
Affiliation(s)
- Y Sagara
- Hakuaikai Social Cooperation, Kagoshima, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Saitama Red Cross Hospital, Saitama, Japan; Iwate Medical University, Morioka, Iwate, Japan; Okayama University Hospital, Okayama, Japan; Cancer Institute Hospital of The Japanese Foundation for Cancer Research, Tokyo, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; Kumamoto University, Kumamoto, Japan; Shizuoka General Hospital, Shizuoka, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kurume General Hospital, Kurume, Fukuoka, Japan; Aomori City Hospital, Aomori, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Tokyo University Hospital, Tokyo, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Chuo University, Tokyo, Japan
| | - M Sawaki
- Hakuaikai Social Cooperation, Kagoshima, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Saitama Red Cross Hospital, Saitama, Japan; Iwate Medical University, Morioka, Iwate, Japan; Okayama University Hospital, Okayama, Japan; Cancer Institute Hospital of The Japanese Foundation for Cancer Research, Tokyo, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; Kumamoto University, Kumamoto, Japan; Shizuoka General Hospital, Shizuoka, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kurume General Hospital, Kurume, Fukuoka, Japan; Aomori City Hospital, Aomori, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Tokyo University Hospital, Tokyo, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Chuo University, Tokyo, Japan
| | - N Taira
- Hakuaikai Social Cooperation, Kagoshima, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Saitama Red Cross Hospital, Saitama, Japan; Iwate Medical University, Morioka, Iwate, Japan; Okayama University Hospital, Okayama, Japan; Cancer Institute Hospital of The Japanese Foundation for Cancer Research, Tokyo, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; Kumamoto University, Kumamoto, Japan; Shizuoka General Hospital, Shizuoka, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kurume General Hospital, Kurume, Fukuoka, Japan; Aomori City Hospital, Aomori, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Tokyo University Hospital, Tokyo, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Chuo University, Tokyo, Japan
| | - T Saito
- Hakuaikai Social Cooperation, Kagoshima, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Saitama Red Cross Hospital, Saitama, Japan; Iwate Medical University, Morioka, Iwate, Japan; Okayama University Hospital, Okayama, Japan; Cancer Institute Hospital of The Japanese Foundation for Cancer Research, Tokyo, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; Kumamoto University, Kumamoto, Japan; Shizuoka General Hospital, Shizuoka, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kurume General Hospital, Kurume, Fukuoka, Japan; Aomori City Hospital, Aomori, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Tokyo University Hospital, Tokyo, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Chuo University, Tokyo, Japan
| | - M Kashiwaba
- Hakuaikai Social Cooperation, Kagoshima, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Saitama Red Cross Hospital, Saitama, Japan; Iwate Medical University, Morioka, Iwate, Japan; Okayama University Hospital, Okayama, Japan; Cancer Institute Hospital of The Japanese Foundation for Cancer Research, Tokyo, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; Kumamoto University, Kumamoto, Japan; Shizuoka General Hospital, Shizuoka, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kurume General Hospital, Kurume, Fukuoka, Japan; Aomori City Hospital, Aomori, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Tokyo University Hospital, Tokyo, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Chuo University, Tokyo, Japan
| | - H Iwata
- Hakuaikai Social Cooperation, Kagoshima, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Saitama Red Cross Hospital, Saitama, Japan; Iwate Medical University, Morioka, Iwate, Japan; Okayama University Hospital, Okayama, Japan; Cancer Institute Hospital of The Japanese Foundation for Cancer Research, Tokyo, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; Kumamoto University, Kumamoto, Japan; Shizuoka General Hospital, Shizuoka, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kurume General Hospital, Kurume, Fukuoka, Japan; Aomori City Hospital, Aomori, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Tokyo University Hospital, Tokyo, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Chuo University, Tokyo, Japan
| | - K Kobayashi
- Hakuaikai Social Cooperation, Kagoshima, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Saitama Red Cross Hospital, Saitama, Japan; Iwate Medical University, Morioka, Iwate, Japan; Okayama University Hospital, Okayama, Japan; Cancer Institute Hospital of The Japanese Foundation for Cancer Research, Tokyo, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; Kumamoto University, Kumamoto, Japan; Shizuoka General Hospital, Shizuoka, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kurume General Hospital, Kurume, Fukuoka, Japan; Aomori City Hospital, Aomori, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Tokyo University Hospital, Tokyo, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Chuo University, Tokyo, Japan
| | - T Nakayama
- Hakuaikai Social Cooperation, Kagoshima, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Saitama Red Cross Hospital, Saitama, Japan; Iwate Medical University, Morioka, Iwate, Japan; Okayama University Hospital, Okayama, Japan; Cancer Institute Hospital of The Japanese Foundation for Cancer Research, Tokyo, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; Kumamoto University, Kumamoto, Japan; Shizuoka General Hospital, Shizuoka, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kurume General Hospital, Kurume, Fukuoka, Japan; Aomori City Hospital, Aomori, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Tokyo University Hospital, Tokyo, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Chuo University, Tokyo, Japan
| | - H Bando
- Hakuaikai Social Cooperation, Kagoshima, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Saitama Red Cross Hospital, Saitama, Japan; Iwate Medical University, Morioka, Iwate, Japan; Okayama University Hospital, Okayama, Japan; Cancer Institute Hospital of The Japanese Foundation for Cancer Research, Tokyo, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; Kumamoto University, Kumamoto, Japan; Shizuoka General Hospital, Shizuoka, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kurume General Hospital, Kurume, Fukuoka, Japan; Aomori City Hospital, Aomori, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Tokyo University Hospital, Tokyo, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Chuo University, Tokyo, Japan
| | - T Mizuno
- Hakuaikai Social Cooperation, Kagoshima, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Saitama Red Cross Hospital, Saitama, Japan; Iwate Medical University, Morioka, Iwate, Japan; Okayama University Hospital, Okayama, Japan; Cancer Institute Hospital of The Japanese Foundation for Cancer Research, Tokyo, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; Kumamoto University, Kumamoto, Japan; Shizuoka General Hospital, Shizuoka, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kurume General Hospital, Kurume, Fukuoka, Japan; Aomori City Hospital, Aomori, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Tokyo University Hospital, Tokyo, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Chuo University, Tokyo, Japan
| | - Y Yamamoto
- Hakuaikai Social Cooperation, Kagoshima, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Saitama Red Cross Hospital, Saitama, Japan; Iwate Medical University, Morioka, Iwate, Japan; Okayama University Hospital, Okayama, Japan; Cancer Institute Hospital of The Japanese Foundation for Cancer Research, Tokyo, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; Kumamoto University, Kumamoto, Japan; Shizuoka General Hospital, Shizuoka, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kurume General Hospital, Kurume, Fukuoka, Japan; Aomori City Hospital, Aomori, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Tokyo University Hospital, Tokyo, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Chuo University, Tokyo, Japan
| | - M Tsuneizumi
- Hakuaikai Social Cooperation, Kagoshima, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Saitama Red Cross Hospital, Saitama, Japan; Iwate Medical University, Morioka, Iwate, Japan; Okayama University Hospital, Okayama, Japan; Cancer Institute Hospital of The Japanese Foundation for Cancer Research, Tokyo, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; Kumamoto University, Kumamoto, Japan; Shizuoka General Hospital, Shizuoka, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kurume General Hospital, Kurume, Fukuoka, Japan; Aomori City Hospital, Aomori, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Tokyo University Hospital, Tokyo, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Chuo University, Tokyo, Japan
| | - M Takahashi
- Hakuaikai Social Cooperation, Kagoshima, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Saitama Red Cross Hospital, Saitama, Japan; Iwate Medical University, Morioka, Iwate, Japan; Okayama University Hospital, Okayama, Japan; Cancer Institute Hospital of The Japanese Foundation for Cancer Research, Tokyo, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; Kumamoto University, Kumamoto, Japan; Shizuoka General Hospital, Shizuoka, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kurume General Hospital, Kurume, Fukuoka, Japan; Aomori City Hospital, Aomori, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Tokyo University Hospital, Tokyo, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Chuo University, Tokyo, Japan
| | - M Yamaguchi
- Hakuaikai Social Cooperation, Kagoshima, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Saitama Red Cross Hospital, Saitama, Japan; Iwate Medical University, Morioka, Iwate, Japan; Okayama University Hospital, Okayama, Japan; Cancer Institute Hospital of The Japanese Foundation for Cancer Research, Tokyo, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; Kumamoto University, Kumamoto, Japan; Shizuoka General Hospital, Shizuoka, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kurume General Hospital, Kurume, Fukuoka, Japan; Aomori City Hospital, Aomori, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Tokyo University Hospital, Tokyo, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Chuo University, Tokyo, Japan
| | - H Kawashima
- Hakuaikai Social Cooperation, Kagoshima, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Saitama Red Cross Hospital, Saitama, Japan; Iwate Medical University, Morioka, Iwate, Japan; Okayama University Hospital, Okayama, Japan; Cancer Institute Hospital of The Japanese Foundation for Cancer Research, Tokyo, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; Kumamoto University, Kumamoto, Japan; Shizuoka General Hospital, Shizuoka, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kurume General Hospital, Kurume, Fukuoka, Japan; Aomori City Hospital, Aomori, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Tokyo University Hospital, Tokyo, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Chuo University, Tokyo, Japan
| | - T Takashima
- Hakuaikai Social Cooperation, Kagoshima, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Saitama Red Cross Hospital, Saitama, Japan; Iwate Medical University, Morioka, Iwate, Japan; Okayama University Hospital, Okayama, Japan; Cancer Institute Hospital of The Japanese Foundation for Cancer Research, Tokyo, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; Kumamoto University, Kumamoto, Japan; Shizuoka General Hospital, Shizuoka, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kurume General Hospital, Kurume, Fukuoka, Japan; Aomori City Hospital, Aomori, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Tokyo University Hospital, Tokyo, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Chuo University, Tokyo, Japan
| | - Y Uemura
- Hakuaikai Social Cooperation, Kagoshima, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Saitama Red Cross Hospital, Saitama, Japan; Iwate Medical University, Morioka, Iwate, Japan; Okayama University Hospital, Okayama, Japan; Cancer Institute Hospital of The Japanese Foundation for Cancer Research, Tokyo, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; Kumamoto University, Kumamoto, Japan; Shizuoka General Hospital, Shizuoka, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kurume General Hospital, Kurume, Fukuoka, Japan; Aomori City Hospital, Aomori, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Tokyo University Hospital, Tokyo, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Chuo University, Tokyo, Japan
| | - Y Hozumi
- Hakuaikai Social Cooperation, Kagoshima, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Saitama Red Cross Hospital, Saitama, Japan; Iwate Medical University, Morioka, Iwate, Japan; Okayama University Hospital, Okayama, Japan; Cancer Institute Hospital of The Japanese Foundation for Cancer Research, Tokyo, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; Kumamoto University, Kumamoto, Japan; Shizuoka General Hospital, Shizuoka, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kurume General Hospital, Kurume, Fukuoka, Japan; Aomori City Hospital, Aomori, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Tokyo University Hospital, Tokyo, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Chuo University, Tokyo, Japan
| | - N Sagawa
- Hakuaikai Social Cooperation, Kagoshima, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Saitama Red Cross Hospital, Saitama, Japan; Iwate Medical University, Morioka, Iwate, Japan; Okayama University Hospital, Okayama, Japan; Cancer Institute Hospital of The Japanese Foundation for Cancer Research, Tokyo, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; Kumamoto University, Kumamoto, Japan; Shizuoka General Hospital, Shizuoka, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kurume General Hospital, Kurume, Fukuoka, Japan; Aomori City Hospital, Aomori, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Tokyo University Hospital, Tokyo, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Chuo University, Tokyo, Japan
| | - H Mukai
- Hakuaikai Social Cooperation, Kagoshima, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Saitama Red Cross Hospital, Saitama, Japan; Iwate Medical University, Morioka, Iwate, Japan; Okayama University Hospital, Okayama, Japan; Cancer Institute Hospital of The Japanese Foundation for Cancer Research, Tokyo, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; Kumamoto University, Kumamoto, Japan; Shizuoka General Hospital, Shizuoka, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kurume General Hospital, Kurume, Fukuoka, Japan; Aomori City Hospital, Aomori, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Tokyo University Hospital, Tokyo, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Chuo University, Tokyo, Japan
| | - Y Ohashi
- Hakuaikai Social Cooperation, Kagoshima, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Saitama Red Cross Hospital, Saitama, Japan; Iwate Medical University, Morioka, Iwate, Japan; Okayama University Hospital, Okayama, Japan; Cancer Institute Hospital of The Japanese Foundation for Cancer Research, Tokyo, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; Kumamoto University, Kumamoto, Japan; Shizuoka General Hospital, Shizuoka, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kurume General Hospital, Kurume, Fukuoka, Japan; Aomori City Hospital, Aomori, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Tokyo University Hospital, Tokyo, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Chuo University, Tokyo, Japan
| |
Collapse
|
30
|
Saito T, Sawaki M, Hozumi Y, Sagawa N, Iwata H, Kashiwaba M, Kawashima H, Kobayashi K, Taira N, Takashima T, Takahashi M, Tsuneizumi M, Nakayama T, Baba S, Bando H, Mizuno T, Yamaguchi M, Yamamoto Y, Uemura Y, Ohashi Y, Mukai H. Abstract P4-11-09: A randomized controlled trial of postoperative adjuvant therapy for elderly breast cancer patients: Comparison of health-related quality of life between clinical trial participants and decliners. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-11-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Health-related quality of life (HRQoL) is one of the important outcomes in cancer control trials and has increasingly become the one of the primary foci. Obtaining informed consent from participants is essential for participation in randomized controlled trials (RCTs), but the participation in these RCTs may directly influence HRQoL, because treatment options are determined according to the allocation schedule. To date, only a few studies have compared HRQoL between clinical trial participants and decliners.
Patients and Method: The National Surgical Adjuvant Study of Breast Cancer 07 (N-SAS BC 07) is a randomized controlled trial in women with HER2-positive primary breast cancer who are over 70 years of age. The primary aim was to investigate the benefit of trastuzumab monotherapy compared with combination therapy using trastuzumab and chemotherapy. The study concept and design were published in concept paper (Sawaki M. et al., Jpn J Clin Oncol. 2011). In this study, patients were randomized to receive either trastuzumab plus chemotherapy or trastuzumab monotherapy. The primary endpoint was disease-free survival, and the secondary endpoints were overall survival, relapse-free survival, safety, HRQoL, comprehensive geriatric assessment (CGA) and cost effectiveness (protocol ID; NCT01104935).
HRQoL and CGA were assessed at registration (baseline), 2 month, 1 year, and 3 years after the start of protocol treatments using the Functional Assessment of Cancer Therapy-General (FACT-G), Hospital Anxiety and Depression Scale (HADS), EuroQol 5 Dimension (EQ-5D), Tokyo Metropolitan Institute of Gerontology (TMIG) index of competence, and the Philadelphia Geriatric Center (PGC) Morale Scale.
The patients who declined to participate in N-SAS BC 07 were registered in a cohort study to prospectively evaluate the subsequent treatment options and prognosis (07-Cohort). The same questionnaire that was used in N-SAS BC 07 was used in 07-Cohort to evaluate HRQoL and CGA at entry.
Results: Patients were enrolled from October 2012 to October 2016. During this period, 275 and 123 patients were registered in N-SAS BC 07 and 07-Cohort, respectively. The mean age at entry of the patients in the N-SAS BC 07 and 07-Cohort groups was 73.9 and 74.6 years, respectively. The questionnaire response rates at baseline in the patients in N-SAS BC 07 and 07-Cohort groups were 89% and 82%, respectively. There were no significant differences in FACT-G, HADS, EQ-5D, or TMIG index of competence at baseline between the groups, but the mean (standard deviation) scores of PGC Morale Scale in N-SAS BC 07 and 07-Cohort groups were 10.8 (3.3) and 9.9 (3.7), respectively, with the scores being significantly greater in the N-SAS BC 07 group (p=0.020, t-test).
Conclusion: The PGC Morale Scale provides a multidimensional approach to assess the psychological state of older people. This study indicated that participation in the RCT did not affect the baseline QoL of elderly patients but suggested that the baseline QoL of the RCT participants was better than decliners.
Citation Format: Saito T, Sawaki M, Hozumi Y, Sagawa N, Iwata H, Kashiwaba M, Kawashima H, Kobayashi K, Taira N, Takashima T, Takahashi M, Tsuneizumi M, Nakayama T, Baba S, Bando H, Mizuno T, Yamaguchi M, Yamamoto Y, Uemura Y, Ohashi Y, Mukai H. A randomized controlled trial of postoperative adjuvant therapy for elderly breast cancer patients: Comparison of health-related quality of life between clinical trial participants and decliners. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-11-09.
Collapse
Affiliation(s)
- T Saito
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - M Sawaki
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - Y Hozumi
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - N Sagawa
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - H Iwata
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - M Kashiwaba
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - H Kawashima
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - K Kobayashi
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - N Taira
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - T Takashima
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - M Takahashi
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - M Tsuneizumi
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - T Nakayama
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - S Baba
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - H Bando
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - T Mizuno
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - M Yamaguchi
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - Y Yamamoto
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - Y Uemura
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - Y Ohashi
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - H Mukai
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| |
Collapse
|
31
|
Yamamoto H, Tanaka H, Ohki N, Kawashima H. The utility of cumulative histogram method with chin emg for diagnosis of REM sleep behavior disorder. Sleep Med 2015. [DOI: 10.1016/j.sleep.2015.02.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
32
|
Kaburaki T, Okinaga K, Takamoto M, Ohtomo K, Yoshida A, Kawashima H, Komae K, Fujino Y. Relationship of ocular disease activities before and after starting infliximab using Behçet's disease ocular attack score 24. Acta Ophthalmol 2015. [DOI: 10.1111/j.1755-3768.2015.0222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- T. Kaburaki
- Department of Ophthalmology; The University of Tokyo Hospital; Tokyo Japan
| | - K.T.R. Okinaga
- Department of Ophthalmology; The University of Tokyo Hospital; Tokyo Japan
| | - M. Takamoto
- Department of Ophthalmology; The University of Tokyo Hospital; Tokyo Japan
| | - K. Ohtomo
- Department of Ophthalmology; The University of Tokyo Hospital; Tokyo Japan
| | - A. Yoshida
- Department of Ophthalmology; Jichi Medical University; Tochigi Japan
| | - H. Kawashima
- Department of Ophthalmology; Jichi Medical University; Tochigi Japan
| | - K. Komae
- Department of Ophthalmology; The University of Tokyo Hospital; Tokyo Japan
| | - Y. Fujino
- Department of Ophthalmology; Japan Community Health Care Organisation; Tokyo Shinjku Medical Center; Shinjyuku-ku Tokyo Japan
| |
Collapse
|
33
|
Tanaka R, Sanada S, Sakuta K, Kawashima H, Kishitani Y. TU-CD-BRA-11: Application of Bone Suppression Technique to Inspiratory/expiratory Chest Radiography. Med Phys 2015. [DOI: 10.1118/1.4925608] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
34
|
Kawashima H, Nagao Y, Ishitobi Y, Kinoshita H, Fukushima S. Bisphosphonates increase serum 1,25-dihydroxyvitamin D in rats via stimulating renal production of the hormone. Contrib Nephrol 2015; 91:140-5. [PMID: 1800007 DOI: 10.1159/000420170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- H Kawashima
- Medicinal Research Laboratories, Yamanouchi Pharmaceutical Co., Ibaraki, Japan
| | | | | | | | | |
Collapse
|
35
|
Ishihara M, Ohmiya N, Nakamura M, Funasaka K, Miyahara R, Ohno E, Kawashima H, Itoh A, Hirooka Y, Watanabe O, Ando T, Goto H. Risk factors of symptomatic NSAID-induced small intestinal injury and diaphragm disease. Aliment Pharmacol Ther 2014; 40:538-47. [PMID: 25041257 DOI: 10.1111/apt.12858] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/09/2013] [Revised: 11/07/2013] [Accepted: 06/11/2014] [Indexed: 12/22/2022]
Abstract
BACKGROUND The aetiology for nonsteroidal anti-inflammatory drug (NSAID)-induced small intestinal injuries has not been well characterised. AIM To determine the risk factors of symptomatic NSAID-induced small intestinal injuries, including diaphragm disease. METHODS Of the 1262 symptomatic patients who underwent videocapsule endoscopy and/or double-balloon enteroscopy, 156 consecutive patients were verified as having taken NSAIDs. Their CYP2C9*2, *3 and *13 single nucleotide polymorphisms (SNPs) were determined by allelic discrimination with Taqman 5'-nuclease assays. RESULTS Of the 156 NSAIDs users, 31 patients (20%) were diagnosed with NSAID-induced small intestinal injury. Multivariate analysis indicated that the presence of comorbidities and the use of oxicams (meloxicam, ampiroxicam and lornoxicam) or diclofenac were associated with an increased risk of NSAID-induced small intestinal injury (adjusted OR: 2.97, 95% CI: 1.05-8.41, P = 0.041 and adjusted OR: 7.05, 95% CI: 2.04-24.40, P = 0.002, respectively). The combination of aspirin and non-aspirin NSAID was more damaging than aspirin alone. Age, sex, concomitant use of proton pump inhibitors, indications for NSAIDs use, duration of NSAIDs use and CYP2C9*2, *3 and *13SNPs were unrelated. The use of meloxicam and CYP2C9*3SNPs were significantly associated with an increased risk for diaphragm disease (adjusted OR: 183.75, 95% CI: 21.34-1582.38; P < 0.0001 and adjusted OR: 12.94, 95% CI: 1.55-108.36, P = 0.018, respectively). CONCLUSION The use of specific NSAIDs and the factors interfering with NSAIDs metabolism might associate with small intestinal injury, especially with diaphragm disease.
Collapse
Affiliation(s)
- M Ishihara
- Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Ogose A, Hotta T, Kawashima H, Yamagiwa H, Endo N, Umezu H. Teaching NeuroImages: Recurrence of a sural intraneural ganglion cyst after sural nerve resection. Neurology 2014; 83:e95-6. [DOI: 10.1212/wnl.0000000000000714] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
37
|
Araki R, Takita A, Ishima T, Kawashima H, Pornsuwancharoen N, Punthawanunt S, Carcasona E, Fujii Y. Impact force measurement of a spherical body dropping onto a water surface. Rev Sci Instrum 2014; 85:075108. [PMID: 25085174 DOI: 10.1063/1.4878629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
We propose a method for measuring the impact force of a spherical body dropping onto a water surface. The velocity of the center of gravity of a metal spherical body, in which a cube corner prism is embedded so that its optical center coincides with the center of gravity of the sphere, is accurately measured using an optical interferometer. The acceleration, displacement, and inertial force of the sphere are calculated from the velocity. The sphere is also observed using a high-speed camera. The uncertainty in measuring the instantaneous value of the impact force with a sampling interval of approximately 1 ms is estimated to be 8 mN, which corresponds to 0.8% of the maximum force of approximately 1.0 N.
Collapse
Affiliation(s)
- R Araki
- School of Science and Technology, Gunma University, Kiryu, Tenjin-cho 1-5-1, 376-8515, Japan
| | - A Takita
- School of Science and Technology, Gunma University, Kiryu, Tenjin-cho 1-5-1, 376-8515, Japan
| | - T Ishima
- School of Science and Technology, Gunma University, Kiryu, Tenjin-cho 1-5-1, 376-8515, Japan
| | - H Kawashima
- School of Science and Technology, Gunma University, Kiryu, Tenjin-cho 1-5-1, 376-8515, Japan
| | - N Pornsuwancharoen
- Faculty of Industry and Technology, Rajamangala University of Technology Isan, Thanyaburi 39 Muh1, Rangsit-Nakhonnayok Rd. Klong Hok, Thanyaburi Pathum Thani 12110, Thailand
| | - S Punthawanunt
- Faculty of Science and Technology, Kasem Bundit University, 1761 Pattanakarn Rd. Suanluang Bangkok 10250, Thailand
| | - E Carcasona
- Faculty of Engineering, University of San Carlos, P. del Rosario Street, Cebu City 6000, Philippines
| | - Y Fujii
- School of Science and Technology, Gunma University, Kiryu, Tenjin-cho 1-5-1, 376-8515, Japan
| |
Collapse
|
38
|
Nakajima J, Okamoto N, Tohyama J, Kato M, Arai H, Funahashi O, Tsurusaki Y, Nakashima M, Kawashima H, Saitsu H, Matsumoto N, Miyake N. De novo EEF1A2 mutations in patients with characteristic facial features, intellectual disability, autistic behaviors and epilepsy. Clin Genet 2014; 87:356-61. [PMID: 24697219 DOI: 10.1111/cge.12394] [Citation(s) in RCA: 60] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2014] [Revised: 03/24/2014] [Accepted: 04/01/2014] [Indexed: 01/07/2023]
Abstract
Eukaryotic elongation factor 1, alpha-2 (eEF1A2) protein is involved in protein synthesis, suppression of apoptosis, and regulation of actin function and cytoskeletal structure. EEF1A2 gene is highly expressed in the central nervous system and Eef1a2 knockout mice show the neuronal degeneration. Until now, only one missense mutation (c.208G > A, p.Gly70Ser) in EEF1A2 has been reported in two independent patients with neurological disease. In this report, we described two patients with de novo mutations (c.754G > C, p.Asp252His and c.364G > A, p.Glu122Lys) in EEF1A2 found by whole-exome sequencing. Common clinical features are shared by all four individuals: severe intellectual disability, autistic behavior, absent speech, neonatal hypotonia, epilepsy and progressive microcephaly. Furthermore, the two patients share the similar characteristic facial features including a depressed nasal bridge, tented upper lip, everted lower lip and downturned corners of the mouth. These data strongly indicate that a new recognizable disorder is caused by EEF1A2 mutations.
Collapse
Affiliation(s)
- J Nakajima
- Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Pediatrics, Tokyo Medical University, Shinjuku, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Iwanaka T, Arai M, Ito M, Kawashima H, Matoba K, Imaizumi S. Challenges of laparoscopic resection of abdominal neuroblastoma with lymphadenectomy. Surg Endosc 2014; 15:489-92. [PMID: 11353967 DOI: 10.1007/s004640090014] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2000] [Accepted: 08/10/2000] [Indexed: 10/28/2022]
Abstract
BACKGROUND The laparoscopic procedure involving total resection of abdominal neuroblastoma combined with lymphadenectomy has not been reviewed in English literature. The aim of this study was to evaluate the significance and accuracy of laparoscopic resection of abdominal neuroblastoma. METHODS Since July 1997, five patients with abdominal neuroblastoma underwent laparoscopic resection combined with lymphadenectomy or sampling of the lymph nodes. The length of operation, intraoperative blood loss, resectability, and complications were retrospectively reviewed and evaluated. RESULTS Four cases were managed laparoscopically, but one case was converted to open procedure because of poor visualization around large vessels. The mean operation time was 135 min and the intraoperative blood loss 52 ml. CONCLUSIONS Good visualization of the primary tumor and large vessels is, arguably, the most important factor for successful completion of this procedure laparoscopically. Precise indicators for laparoscopic resection of abdominal neuroblastoma provide a better prognosis and a good quality of life for children with neuroblastoma.
Collapse
Affiliation(s)
- T Iwanaka
- Department of Surgery, Saitama Children's Medical Center, 2100 Magome, Iwatsuki, Saitama 339-8551, Japan.
| | | | | | | | | | | |
Collapse
|
40
|
Cong GW, Suzuki K, Kim SH, Tanizawa K, Namiki S, Kawashima H. Demonstration of a 3-dB directional coupler with enhanced robustness to gap variations for silicon wire waveguides. Opt Express 2014; 22:2051-2059. [PMID: 24515214 DOI: 10.1364/oe.22.002051] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
We demonstrate a robust 3-dB directional coupler which has a narrow silicon wire core and a wide gap. Sensitivity to the gap variation is decreased to one tenth that of a conventional directional coupler. Better spectral stability due to the enhanced robustness to waveguide geometrical fluctuations was experimentally verified.
Collapse
|
41
|
Shibanuma K, Arai T, Hasegawa K, Hoshi R, Kamiya K, Kawashima H, Kubo H, Masaki K, Saeki H, Sakurai S, Sakata S, Sakasai A, Sawai H, Shibama Y, Tsuchiya K, Tsukao N, Yagyu J, Yoshida K, Kamada Y, Mizumaki S, Hayakawa A, Takigami H, Barabaschi P, Davis S, Peyrot M, Phillips G. Assembly study for JT-60SA tokamak. Fusion Engineering and Design 2013. [DOI: 10.1016/j.fusengdes.2012.12.011] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
42
|
Nakamura M, Ohmiya N, Hirooka Y, Miyahara R, Ando T, Watanabe O, Itoh A, Kawashima H, Ohno E, Kinoshita T, Goto H. Endoscopic diagnosis of follicular lymphoma with small-bowel involvement using video capsule endoscopy and double-balloon endoscopy: a case series. Endoscopy 2013. [PMID: 23208779 DOI: 10.1055/s-0032-1325867] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
The aims of this study were to compare the detection rates of gastrointestinal follicular lymphoma lesions by video capsule endoscopy (VCE) and double-balloon endoscopy (DBE), and to determine the pathologic diagnostic yields of DBE-directed biopsies. A total of 27 consecutive patients were enrolled. No significant difference in detection rates was observed in 12 patients who underwent total enteroscopy at both VCE and DBE. Pathologic diagnostic yields stratified by location were 91 % in the proximal duodenum at esophagogastroduodenoscopy, 88 % in the jejunum at antegrade DBE, 52 % in the ileum at retrograde DBE, and 57 % in the terminal ileum at colonoscopy. VCE and DBE were helpful in determining treatment in 44 % of patients.
Collapse
Affiliation(s)
- M Nakamura
- Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Ohmiya N, Nakamura M, Funasaka K, Miyahara R, Ohno E, Kawashima H, Itoh A, Hirooka Y, Toyota H, Goto H. Intestinal Phlebectasias Treated by Endoscopic Injection Sclerotherapy at Double-Balloon Endoscopy. ACTA ACUST UNITED AC 2013. [DOI: 10.1016/s2212-0971(13)70105-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
44
|
Hoshino M, Sugito K, Kawashima H, Goto S, Kaneda H, Furuya T, Hosoda T, Masuko T, Ohashi K, Inoue M, Ikeda T, Tomita R, Koshinaga T. Prediction of contralateral inguinal hernias in children: a prospective study of 357 unilateral inguinal hernias. Hernia 2013; 18:333-7. [PMID: 23644774 PMCID: PMC4037557 DOI: 10.1007/s10029-013-1099-2] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2012] [Accepted: 04/26/2013] [Indexed: 11/26/2022]
Abstract
Purpose Previously, we established a pre-operative risk scoring system to predict contralateral inguinal hernia in children with unilateral inguinal hernias. The current study aimed to verify the usefulness of our pre-operative scoring system. Methods This was a prospective study of patients undergoing unilateral inguinal hernia repair from 2006 to 2009 at a single institution. Gender, age at initial operation, birth weight, initial operation side, and the pre-operative risk score were recorded. We analyzed the incidence of contralateral inguinal hernia, risk factors, and the usefulness of our pre-operative risk scoring system. The follow-up period was 36 months. We used forward multiple logistic regression analysis to predict contralateral hernia. Results Of the 372 patients who underwent unilateral hernia repair, 357 (96.0 %) were completely followed-up for 36 months, and 23 patients (6.4 %) developed a contralateral hernia. Left-sided hernia (OR = 5.5, 95 %, CI = 1.3–24.3, p = 0.023) was associated with an increased risk of contralateral hernia. The following covariates were not associated with contralateral hernia development: gender (p = 0.702), age (p = 0.215), and birth weight (p = 0.301). The pre-operative risk score (cut-off point = 4.5) of the patients with a contralateral hernia was significantly higher, compared with the patients without a contralateral hernia using the area under the receiver operating characteristic curve (p = 0.024). Conclusions Using multivariate analysis, we confirmed usefulness of our pre-operative scoring system and initial side of the inguinal hernia, together, for the prediction of contralateral inguinal hernia in children.
Collapse
Affiliation(s)
- M. Hoshino
- Department of Pediatric Surgery, Nihon University School of Medicine, 30-1, Ohyaguchikami-cho, Itabashi-ku, Tokyo 173-8610 Japan
| | - K. Sugito
- Department of Pediatric Surgery, Nihon University School of Medicine, 30-1, Ohyaguchikami-cho, Itabashi-ku, Tokyo 173-8610 Japan
| | - H. Kawashima
- Department of Pediatric Surgery, Nihon University School of Medicine, 30-1, Ohyaguchikami-cho, Itabashi-ku, Tokyo 173-8610 Japan
| | - S. Goto
- Department of Pediatric Surgery, Nihon University School of Medicine, 30-1, Ohyaguchikami-cho, Itabashi-ku, Tokyo 173-8610 Japan
| | - H. Kaneda
- Department of Pediatric Surgery, Nihon University School of Medicine, 30-1, Ohyaguchikami-cho, Itabashi-ku, Tokyo 173-8610 Japan
| | - T. Furuya
- Department of Pediatric Surgery, Nihon University School of Medicine, 30-1, Ohyaguchikami-cho, Itabashi-ku, Tokyo 173-8610 Japan
| | - T. Hosoda
- Department of Pediatric Surgery, Nihon University School of Medicine, 30-1, Ohyaguchikami-cho, Itabashi-ku, Tokyo 173-8610 Japan
| | - T. Masuko
- Department of Pediatric Surgery, Nihon University School of Medicine, 30-1, Ohyaguchikami-cho, Itabashi-ku, Tokyo 173-8610 Japan
| | - K. Ohashi
- Department of Pediatric Surgery, Nihon University School of Medicine, 30-1, Ohyaguchikami-cho, Itabashi-ku, Tokyo 173-8610 Japan
| | - M. Inoue
- Department of Pediatric Surgery, Nihon University School of Medicine, 30-1, Ohyaguchikami-cho, Itabashi-ku, Tokyo 173-8610 Japan
| | - T. Ikeda
- Department of Pediatric Surgery, Nihon University School of Medicine, 30-1, Ohyaguchikami-cho, Itabashi-ku, Tokyo 173-8610 Japan
| | - R. Tomita
- Department of Pediatric Surgery, Nihon University School of Medicine, 30-1, Ohyaguchikami-cho, Itabashi-ku, Tokyo 173-8610 Japan
| | - T. Koshinaga
- Department of Pediatric Surgery, Nihon University School of Medicine, 30-1, Ohyaguchikami-cho, Itabashi-ku, Tokyo 173-8610 Japan
| |
Collapse
|
45
|
Cong GW, Matsukawa T, Chiba T, Tadokoro H, Yanagihara M, Ohno M, Kawashima H, Kuwatsuka H, Igarashi Y, Masahara M, Ishikawa H. Large current MOSFET on photonic silicon-on-insulator wafers and its monolithic integration with a thermo-optic 2 × 2 Mach-Zehnder switch. Opt Express 2013; 21:6889-6894. [PMID: 23546071 DOI: 10.1364/oe.21.006889] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
n-channel body-tied partially depleted metal-oxide-semiconductor field-effect transistors (MOSFETs) were fabricated for large current applications on a silicon-on-insulator wafer with photonics-oriented specifications. The MOSFET can drive an electrical current as large as 20 mA. We monolithically integrated this MOSFET with a 2 × 2 Mach-Zehnder interferometer optical switch having thermo-optic phase shifters. The static and dynamic performances of the integrated device are experimentally evaluated.
Collapse
Affiliation(s)
- G W Cong
- Network Photonics Research Center, National Institute of Advanced Industrial Science and Technology (AIST), Umezono 1-1-1, Tsukuba, Ibaraki 305-8568, Japan.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Kodaira S, Yasuda N, Konishi T, Kitamura H, Kurano M, Kawashima H, Uchihori Y, Ogura K, Benton E. Calibration of CR-39 with atomic force microscope for the measurement of short range tracks from proton-induced target fragmentation reactions. RADIAT MEAS 2013. [DOI: 10.1016/j.radmeas.2012.10.001] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
47
|
Kodaira S, Yasuda N, Kawashima H, Kurano M, Naka S, Ota S, Ideguchi Y, Hasebe N, Ogura K. Detection threshold control of CR-39 plastic nuclear track detectors for the selective measurement of high LET secondary charged particles. RADIAT MEAS 2011. [DOI: 10.1016/j.radmeas.2011.08.015] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
48
|
Kawashima H, Nishimata S, Ishii C, Yamanaka G, Kashiwagi Y, Takekuma K, Hoshika A, Watanabe Y. New treatment of free-radical scavenger in adrenoleukodystrophy. J Clin Pharm Ther 2011; 36:412-5. [PMID: 21463348 DOI: 10.1111/j.1365-2710.2011.01267.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
WHAT IS KNOWN AND OBJECTIVE Adrenoleukodystrophy (ALD) is an X-linked disorder and characterized by the accumulation of saturated very long-chain fatty acids. Treatment is still unsatisfactory. Our objective is to report on the effect of the free-radical scavenger, edaravone, in a patient with ALD. CASE SUMMARY The patient was given edaravone intravenously twice. D-ROM in cerebral spinal fluid decreased dramatically, and a shortening of neuronal transmission time as estimated on somatosensory evoked potential was observed. After terminating the treatment, his symptoms progressively reappeared. WHAT IS NEW AND CONCLUSION This is the first report of the use of edaravone in ALD. The drug is apparently effective in improving symptoms of ALD and should be evaluated more formally.
Collapse
Affiliation(s)
- H Kawashima
- Department of Paediatrics, Tokyo Medical University, Tokyo, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Kashiwagi Y, Suzuki S, Watanabe K, Nishimata S, Kawashima H, Takekuma K, Hoshika A. Sudden unexpected death associated with ileocecal duplication cyst and clinical review. Clin Med Insights Pediatr 2010; 4:25-8. [PMID: 23761993 PMCID: PMC3667037 DOI: 10.4137/cmped.s4850] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Duplications of the alimentary tract are very rare. A one-month-old female presented with symptoms of anorexia, vomiting and continuous watery diarrhea. The plain abdominal radiograph showed thickened intestinal wall and signs of small bowel obstruction. The fevers, vomiting, and continuous wartery diarrhea persisted despite antibiotics, and worsened. The patient failed to respond to medical managements, 27 hours after admission, the patient died due to multiple organ failures. The autopsy was performed, small bowel obstruction due to an ileocecal duplication cyst (3 × 3 cm) was recognized. The ileocecal duplication cyst was attached to the ileum which was changed edematous and necrotic. This potential diagnosis should be borne in mind for a patient who complains of abdominal symptoms with an unknown cause, and duplication cyst should be recognized as a fatal cause in infant.
Collapse
Affiliation(s)
- Y Kashiwagi
- Department of Pediatrics, Tokyo Medical University, Tokyo, Japan
| | | | | | | | | | | | | |
Collapse
|
50
|
Jareonkitmongkol S, Kawashima H, Shirasaka N, Shimizu S, Yamada H. Production of Dihomo-gamma-Linolenic Acid by a Delta5-Desaturase-Defective Mutant of Mortierella alpina 1S-4. Appl Environ Microbiol 2010; 58:2196-200. [PMID: 16348734 PMCID: PMC195755 DOI: 10.1128/aem.58.7.2196-2200.1992] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
A mutant, which has low Delta5-desaturase activity, of an arachidonic acid-producing fungus, Mortierella alpina 1S-4, was shown to be a novel potent producer of dihomo-gamma-linolenic acid (DHGA). On submerged culture under optimal conditions for 6 days at 28 degrees C in a 10-liter fermentor, the mutant produced 3.2 g of DHGA per liter of culture broth (123 mg/g of dry mycelia), which accounted for 23.4% of the total mycelial fatty acids. Mycelial arachidonic acid amounted to only 19 mg/g of dry mycelia (0.5 g/liter of culture broth), which accounted for 3.7% of the total mycelial fatty acids. The other major mycelial fatty acids were palmitic acid (11.0%), stearic acid (12.8%), oleic acid (22.7%), linoleic acid (8.9%), gamma-linolenic acid (6.5%), and lignoceric acid (7.8%). More than 97 mol% of the DHGA produced was found in the triglyceride fraction irrespective of the growth temperature employed (12 to 28 degrees C).
Collapse
Affiliation(s)
- S Jareonkitmongkol
- Department of Agricultural Chemistry, Kyoto University, Sakyo-ku, Kyoto 606, Japan
| | | | | | | | | |
Collapse
|